한글목차

Recardio가 개발 중인 듀토글립틴(REC-01)은 강력하고 선택적인 디펩티딜펩티데이즈4(DPP4) 억제제입니다. 듀토글립틴은 SC 주사로 투여됩니다.

HEAL-MI로 명명된 이 중요한 국제 공동연구는 좌심실박출률(LVEF)이 확인되지 않은 STEMI AMI 환자 4,000명을 등록하는 것으로, 스크리닝을 용이하게 함으로써 총 등록자 수를 가속화할 것입니다. 1차 평가변수는 임상적 평가변수, 2차 평가변수는 삶의 질 평가입니다. 이 권고에 따라 2022년 개시를 목표로 임상시험을 준비 중이며, 미국, 유럽, 중국 등 세계 주요 지역에서 환자를 등록할 예정입니다.

앞으로 몇 년동안 심근경색증 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 듀토글립틴의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 다른 심근경색 치료제들도 듀토글립틴과 치열한 시장 경쟁을 벌이고 있으며, 조만간 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 심근경색 치료제 듀토글립틴(Dutogliptin) 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 심근경색 듀토글립틴 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 듀토글립틴 시장 평가

• 심근경색 듀토글립틴 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 심근경색 치료제 듀토글립틴 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"Dutogliptin Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about dutogliptin for myocardial infarction in the seven major markets. A detailed picture of the dutogliptin for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the dutogliptin for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the dutogliptin market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

Dutogliptin (REC-01), being developed by Recardio, is a potent and selective inhibitor of dipeptidyl peptidase 4 (DPP4). Dutogliptin is administered via SC injection.

The pivotal global trial, named HEAL-MI, will enroll 4,000 AMI patients with STEMI but not specified left ventricular ejection fraction (LVEF) and with facilitated screening procedures, which will accelerate the total enrollment. The primary endpoint is a combined clinical endpoint with a quality-of-life evaluation as a secondary endpoint. Based on this advice, preparations are underway for the trial which was intended to start in 2022 and will enroll patients in the key global regions - the US, Europe, and China.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the dutogliptin description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on dutogliptin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the dutogliptin research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around dutogliptin.
• The report contains forecasted sales of dutogliptin for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for dutogliptin in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dutogliptin Analytical Perspective by DelveInsight

• In-depth Dutogliptin Market Assessment

This report provides a detailed market assessment of dutogliptin for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Dutogliptin Clinical Assessment

The report provides the clinical trials information of dutogliptin for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence dutogliptin dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to dutogliptin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of dutogliptin in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of dutogliptin from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the dutogliptin in myocardial infarction.

Key Questions:

• What is the product type, route of administration and mechanism of action of dutogliptin?
• What is the clinical trial status of the study related to dutogliptin in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the dutogliptin development?
• What are the key designations that have been granted to dutogliptin for myocardial infarction?
• What is the forecasted market scenario of dutogliptin for myocardial infarction?
• What are the forecasted sales of dutogliptin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to dutogliptin for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

Table of Contents

1. Report Introduction

2. Dutogliptin Overview in myocardial infarction

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Dutogliptin Market Assessment

• 5.1. Market Outlook of Dutogliptin in myocardial infarction
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Dutogliptin in the 7MM for myocardial infarction
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Dutogliptin in the United States for myocardial infarction
  • 5.3.2. Market Size of Dutogliptin in Germany for myocardial infarction
  • 5.3.3. Market Size of Dutogliptin in France for myocardial infarction
  • 5.3.4. Market Size of Dutogliptin in Italy for myocardial infarction
  • 5.3.5. Market Size of Dutogliptin in Spain for myocardial infarction
  • 5.3.6. Market Size of Dutogliptin in the United Kingdom for myocardial infarction
  • 5.3.7. Market Size of Dutogliptin in Japan for myocardial infarction

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options